Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Nonseminomatous germ cell tumor × cabazitaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 28 Neoplasm Metastasis 6 Recurrence 5 Breast Neoplasms 4 Stomach Neoplasms 3 Prostate Cancer Metastatic 3 Neoplastic Cells, Circulating 3 Carcinoma, Transitional Cell 3 Ovarian Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Brain Neoplasms 2 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Prostatic Neoplasms, Castration-Resistant 1 Prostate Cancer, Hereditary, 7 1 Penile Neoplasms 1 Nonseminomatous germ cell tumor 1 Metastatic Castration-resistant Prostate Cancer, MCRPC 1 Metastatic Castration-resistant Prostate Cancer 1 Metastatic Breast Cancer With Intracranial Metastases 1 Lung Neoplasms 1 Liposarcoma 1 Hormone-Resistant Prostate Cancer 1 Head and Neck Neoplasms 1 Glioblastoma 1 Esophageal Neoplasms 1 Diarrhea 1 Colorectal Neoplasms 1 Castrate-resistant Metastatic Prostate Cancer 1

Interventions

tremelimumab 1 trametinib 1 pembrolizumab 1 fludarabine phosphate 1 fludarabine 1 durvalumab 1 dabrafenib 1 cabozantinib 1 cabazitaxel 1 Etoposide 1 Drug Therapy 1 Cyclophosphamide 1 Brentuximab Vedotin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02115165 2016-06-09

CABA-GCT

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Unknown

Nonseminomatous germ cell tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡